DOCSLIB.ORG

Evaluation of Experimental Autoimmune Uveitis in Mice Treated with FTY720

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Experimental Autoimmune Uveitis in Mice Treated with FTY720 Immunology and Microbiology Evaluation of Experimental Autoimmune Uveitis in Mice Treated with FTY720 Alessandra Gonc¸alves Commodaro,1 Jean Pierre S. Peron,2 Camila Takao Lopes,3 Christina Arslanian,2 Rubens Belfort, Jr,1 Luiz Vicente Rizzo,2,4 and Valquiria Bueno3 PURPOSE. FTY720 (fingolimod) is an immunomodulatory drug the study of human idiopathic uveitis. This disease can be capable of preventing T-cell migration to inflammatory sites by induced in susceptible primates and rodents after immuni- binding to and subsequently downregulating the expression of zation with retinal self-antigens, such as interphotoreceptor sphingosine-1 phosphate receptor 1 (S1P1) leading in turn to retinoid-binding protein (IRBP) or S-antigen (arrestin), or by T-cell retention in lymphoid organs. Additional effects of the adoptive transfer of uveitis antigen-specific T cells.1–3 FTY720 by increasing functional activity of regulatory T cells It has been shown that autoreactive Th1 cells mediate have recently been demonstrated, raising the conversion of EAU4,5; thus, its induction is correlated with the production of conventional T cells into regulatory T cells and affecting the IFN-␥ by T cells. Moreover, inhibition of Th1 responses by sequestration of regulatory T cells in normal mice. In this anti–IL-12 treatment suppresses the disease.6 Recently, Th17 study, the action of FTY720 in the ocular autoimmune model in cells have also been suggested to be involved in EAU.7,8 mice was investigated. The EAU mouse model has contributed significantly to the METHODS. Mice were immunized with 161-180 peptide and establishment of parameters for the evaluation of possible 3 pertussis toxin and were treated with 1 mg/kg/d FTY720 by therapies for posterior uveitis in humans. Studies of genetic 9 gavage (7–21 days postimmunization [dpi]) or left untreated. susceptibility and resistance to EAU, characterization of 10 Spleen cells, harvested 21 dpi, were cultured and assayed for uveitogenic epitopes, and studies of tolerance in EAU by 11,12 cytokine production. Draining lymph node, spleen, and eye anterior chamber-associated immune deviation or by sys- 13,14 cells 21 dpi were assayed for quantification of T-cell popula- tems of oral tolerance have obtained success according to tions. Disease severity was evaluated by histologic examination this model. of the enucleated eyes at 21 and 49 dpi. In addition, anti–IRBP In 2005, our group demonstrated that treatment with an ␣4 antibodies were analyzed by ELISA. active peptide inhibitor, which targets the ␣4 integrin of the VLA-4 adhesion molecule, had a significant ameliorating effect RESULTS. FTY720 was effective in suppressing the experimental on EAU.15 Clinical ocular pathology can also be prevented by autoimmune uveitis score. Although there was a reduction in the administration of recombinant Galectin-1 (rGal-1) either the number of eye-infiltrating cells, FTY did not prevent Treg early or late during the course of EAU.16 Associated mecha- accumulation at this site. FTY720 leads to a significant increase ϩ ϩ ϩ ϩ nisms were recently described because Gal-1 induces dendritic of CD4 IFN-␥ and CD4 Foxp3 cell percentages in lymph cells to secrete IL-27, which induce T cells to become Tr1 nodes, suggesting that this site could be the source of Treg IL-10–secreting cells. In addition, IL-27 is able to directly sup- cells found in the eye. press Th17 cells.17 Altogether, these results have shown that CONCLUSIONS. The data showed that treatment in vivo with manipulating the immune system to upregulate Th2- and FTY720 was able to suppress EAU in mice. These results are T-regulatory cytokines can prevent inflammation and EAU de- indicative of the possible therapeutic use of FTY720 in ocular velopment.18–20 autoimmune processes. (Invest Ophthalmol Vis Sci. 2010;51: Recently, various reports clearly showed that some mol- 2568–2574) DOI:10.1167/iovs.09-4769 ecules, such as LX211 (voclosporin),21 anti–IL-17,22 and ␣-melanocyte–stimulating hormone,23 were effective in sup- xperimental autoimmune uveitis (EAU) is an organ-specific, pressing EAU. In this context, fingolimod (FTY720; Novartis, ET cell–mediated disease that targets the posterior pole of Basel, Switzerland) is an immunomodulatory drug capable of the eye. It is also a valuable, well-characterized model for preventing T-cell infiltration by binding to and subsequently downregulating the expression of sphingosine-1 phosphate 24 receptor 1 (S1P1). S1P1 signaling is required for T-cell 25 1 3 egress from secondary lymphoid tissue. Therefore, block- From the Vision Institute and the Immunology Division, Univer- ing this pathway leads to T-cell retention in lymphoid organs sidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil; the 2Department of Immunology, University of Sa˜o Paulo and the 4Albert Einstein Jewish and prevents their migration to inflammatory sites. Institute for Education and Research, Sa˜o Paulo, Brazil. In transplantation, FTY720 prolonged mouse (C3H to Supported by Fundac¸a˜o de Amparo a Pesquisa do Estado de Sa˜o BALB/c) corneal allograft survival by reducing the infiltration of ϩ ϩ Paulo Grant 04/14727-0; Conselho Nacional de Desenvolvimento CD4 and F4/80 cells and decreasing allogeneic T-cell prolif- Científico e Tecnolo´gico; Pan-American Ophthalmological Foundation eration.26 In rats, penetrating keratoplasty was performed Grant 2007; and FADA-Universidade Federal de Sa˜o Paulo. (Fisher to Lewis), and FTY720 treatment caused significant Submitted for publication October 14, 2009; revised November rejection-free graft survival and reduction of CD4ϩ, CD8ϩ, and 18, 2009; accepted December 5, 2009. NK infiltrating cells.27 In addition, FTY720 treatment sup- Disclosure: , None; , A. Gonc¸alves Commodaro J.P.S. Peron pressed the incidence and intensity of EAU in Lewis rats im- None; C.T. Lopes, None; C. Arslanian, None; R. Belfort, Jr, None; munized with S-antigen. Suppression of antibody serum levels L.V. Rizzo, None; V. Bueno, None 28 Corresponding author: Valquiria Bueno, Laboratory of Experimental and antigen-specific lymphocyte proliferation was observed. Immunology, Immunology Division, Universidade Federal de Sa˜o Paulo, In B10.RIII mice induced to autoimmune uveoretinitis, the Rua Botucatu 862 4o andar, Sa˜o Paulo, Brazil; [email protected]. retinal infiltrate was prevented by FTY720 treatment 2 days Investigative Ophthalmology & Visual Science, May 2010, Vol. 51, No. 5 2568 Copyright © Association for Research in Vision and Ophthalmology Downloaded from iovs.arvojournals.org on 10/01/2021 IOVS, May 2010, Vol. 51, No. 5 EAU in Mice 2569 before disease onset. This finding was associated with the blinded fashion by examining six sections cut at different levels for suppression of histologic disease. A single dose of fingolimod each eye. Severity of EAU was scored on a scale from 0 (no disease) to administered after disease onset (14 days after induction) not 4 (maximum disease) in half-point increments, according to a semi- only abolished retinal infiltrates but prevented disease relapse quantitative system described previously3 and according to lesion type, for at least 3 weeks.29 size, and number. In brief, the minimal criterion to score an eye as Additional effects of FTY720 have recently been demon- positive by histopathology was inflammatory cell infiltration of the strated by increasing the functional activity of regulatory T ciliary body, choroids, or retina (EAU grade 0.5). Progressively higher cells, enabling the conversion of conventional T cells into grades were assigned for the presence of discrete lesions in the tissue regulatory T cells30–32 and affecting the sequestration of regu- such as vasculitis, granuloma formation, retinal folding or detachment, latory T cells in normal mice.31 and photoreceptor damage. Daniel et al.32 used a model of experimental colitis to evaluate the role of FTY720 in disease development. It was Determination of Cytokine Production observed that FTY720 substantially reduced all clinical, his- Spleen cells harvested 21 dpi were cultured in 24-well plates (106 topathologic, macroscopic, and microscopic parameters of co- cells/well) and stimulated with 30 ␮g/mL IRBP. Supernatants were litis analyzed. FTY720 treatment caused a downregulation of collected for cytokine analysis after 48 or 72 hours and were stored at IL-12p70 and TNF-alpha expression in colon protein extracts. ϩ Ϫ80°C until assayed. The level of IFN-␥ was assessed by ELISA using a LP CD4 cells from Peyer’s patches were evaluated by ELISA kit from BD PharMingen (La Jolla, CA), and the level of IL-17 was and presented a dose-dependent increase of IL-10 and TGF-beta assessed by ELISA using a kit from eBioscience (San Diego, CA). All kits expression in FTY720-treated mice. In addition, induction of were used according to the manufacturers’ instructions. FoxP3 and CTLA4 protein expression was observed in colon. This findings provide evidence that, in addition to its well- established effects on migration, FTY720 leads to specific Flow Cytometry Analysis downregulation of proinflammatory signals while it simulta- Eyes. Eyes were nucleated and gently crushed with the flat surface ϩ ϩ neously induces the functional activity of CD4 CD25 Treg of a sterile syringe plunger in a plastic Petri dish containing PBS. The cells.32 cell suspension was then filtered through a 400-␮m stainless iron mesh Zhang et al.33 evaluated experimental autoimmune neuritis and a 70-␮m nylon cell strainer (BD Biosciences-Labware, Bedford, MA) (EAN) in rats and observed by flow cytometry that treatment and adjusted for 5 ϫ 105 cells/tube for staining with rat anti–mouse with FTY720 at disease onset (day 10 until day 18) caused an CD25Pe and rat anti–mouse CD4PerCP-Cy5.5 (eBioscience). After in- increase in Foxp3 cells in blood but a decrease in lymph node. cubation for 30 minutes, cells were washed with PBS, fixed for 15 In sciatic nerves of EAN rats, FTY720 increased the percent- minutes with 1% paraformaldehyde, permeabilized for 6 minutes with ϩ ages of Foxp3 cells as observed by immunohistochemistry.33 0.2% Triton X-100, and stained with rat anti–mouse Foxp3 FITC for 30 Considering that different T-cell subsets may present uveito- minutes (eBioscience).
Load more

Recommended publications
  • Application Withdrawal Assessment Report for Luveniq
    Committee for Medicinal Products for Human Use (CHMP) Assessment report Luveniq voclosporin Procedure No.: EMEA/H/C/002069//0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier.................................................................................... 5 1.2. Steps taken for the assessment of the product ....................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 8 2.2.1. Introduction ................................................................................................... 8 2.2.2. Active Substance............................................................................................. 8 2.2.3. Finished Medicinal Product .............................................................................
    [Show full text]
  • Benlysta® (Belimumab)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1227-6 Program Prior Authorization/Notification Medication Benlysta® (belimumab)* *This program applies to the subcutaneous formulation of belimumab P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021 Effective Date 10/1/2021; Oxford only: 10/1/2021 1. Background: Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 2. Coverage Criteria: A. Systemic Lupus Erythematosus 1. Initial Authorization a. Benlysta will be approved based on all of the following criteria: (1) Diagnosis of systemic lupus erythematosus -AND- (2) Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB] -AND- (3) Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate] -AND- (4) Patient does not have severe active central nervous system lupus -AND- (5) Patient is not receiving Benlysta in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)] © 2021 UnitedHealthcare Services, Inc. 1 (b) Lupkynis (voclosporin) Authorization will be issued for 12 months.
    [Show full text]
  • Prior Authorization Lupkynis™ (Voclosporin Capsules)
    Cigna National Formulary Coverage Policy Prior Authorization Lupkynis™ (voclosporin capsules) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 79744 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 3 Revision History ................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Lupkynis (Voclosporin Capsules) Annual Review Date: 02/18/2021
    Policy: Lupkynis (voclosporin capsules) Annual Review Date: 02/18/2021 Last Revised Date: 02/18/2021 OVERVIEW Lupkynis, a calcineurin inhibitor immunosuppressant, is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adults with active lupus nephritis.1 Safety and efficacy have not been established in combination with cyclophosphamide and is not recommended. The recommended starting dose is 23.7 mg twice daily taken on an empty stomach, used in combination with mycophenolate mofetil and corticosteroids. Dose modifications are required based on estimated glomerular filtration rate (eGFR). Lupkynis is not recommended if baseline eGFR is ≤ 45 mL/min/1.73 m2 unless the benefit exceeds the risk. If therapeutic benefit is not apparent by Week 24, consider discontinuation of Lupkynis. POLICY STATEMENT This policy involves the use of Lupkynis. Prior authorization is recommended for pharmacy benefit coverage of Lupkynis. Approval is recommended for those who meet the conditions of coverage in the Criteria and Initial/Extended Approval for the diagnosis provided. Conditions Not Recommended for Approval are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis. Because of the specialized skills required for evaluation and diagnosis of patients treated with Lupkynis as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Lupkynis be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.
    [Show full text]
  • Changes to the Drug Formularies
    Published September 2, 2021 The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in April 2021 by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Progressive Healthcare Reform Formulary C. Changes to the Highmark Healthcare Reform Essential Formulary D. Changes to the Highmark Core Formulary E. Changes to the Highmark National Select Formulary F. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs Section II. Highmark Medicare Part D Formularies A. Changes to the Highmark Medicare Part D 5-Tier Incentive Formulary B. Changes to the Highmark Medicare Part D 5-Tier Closed Formulary C. Additions to the Specialty Tier D. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Quantity Level Limit (QLL) Program As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides a secure, web-based portal between providers and health insurance companies.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • Future Therapies for Chronic Noninfectious Uveitis New Drugs and Innovative Drug Delivery Systems Will Pave the Way for Future Treatments in Uveitis
    MEDICAL RETINA FEATURE STORY Future Therapies for Chronic Noninfectious Uveitis New drugs and innovative drug delivery systems will pave the way for future treatments in uveitis. BY EMMETT T. CUNNINGHAM, JR, MD, PHD, MPH ocal and systemic corticosteroids constitute first-line therapy for virtually all patients with noninfectious uveitis.1 Prolonged corticosteroid use can produce No fewer than 12 therapies are now toxic effects, however, and so corticosteroid-sparing in clinical development for chronic Limmunomodulatory therapies (IMTs) have assumed an increasingly important role in the management of chronic noninfectious uveitis. These ocular inflammation.2,3 The more commonly used non- therapies represent both novel corticosteroid immunosuppressive agents include antime- agents and established drugs. tabolites, such as mycophenoloate mofetil, methotrexate, and azathioprine; leukocyte signaling inhibitors, such as cyclosporine and tacrolimus; tumor necrosis factor (TNF)-α inhibitors, such as infliximab (Remicade, Janssen), adali- novel intravitreal formulation of the immunosuppres- mumab (Humira, Abbott Laboratories), and golimumab sant sirolimus, which blocks leukocyte activation and (Simponi, Janssen); and the alkylating agents cyclophospha- the production of inflammatory cytokines (including mide and chlorambucil, which are reserved for the most IL-2, IL-4, and IL-5) by inhibiting mammalian target of severe vision- or life-threatening conditions.2,4 These and rapamycin (mTOR). DE-109 has been administered other currently available agents are summarized in Table 1. both subconjunctivally and intravitreally in clinical stud- Each of the currently available treatments for chronic ies.5,6 When given intravitreally, DE-109 forms a slowly noninfectious uveitis has its own issues, however.3,4 All have dissolving depot in the vitreous humor.
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Drugs in Development for Prophylaxis of Rejection in Kidney-Transplant Recipients
    Transplant Research and Risk Management Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Drugs in development for prophylaxis of rejection in kidney-transplant recipients Marion Lee Sanders1 Abstract: Transplantation is the preferred treatment option for individuals with end-stage Anthony James Langone2 renal disease. Individuals who undergo transplantation must chronically be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure graft survival. Current 1Department of Medicine, Division of Nephrology and Hypertension, rejection prophylaxis consists of using a combination of calcineurin inhibitors, mTOR inhibi- University of Iowa, Iowa City, IA, tors, antimetabolite agents, and/or corticosteroids. These agents have collectively improved 2Department of Medicine, Division of Nephrology and Hypertension, the short-term outcomes of renal transplantation, but improvements in late/chronic graft loss Vanderbilt University Medical Center, and recipient survival have lagged significantly behind challenging the field of transplantation Nashville, TN, USA to develop novel prophylactic agents. There have been several clinical trials conducted within the last 5 years in an attempt to bring such novel agents to the commercial market. These trials For personal use only. have resulted in the US Food and Drug Administration (FDA) approval of extended-release tacrolimus, as well as belatacept, which has the potential to replace calcineurin inhibitors for rejection prophylaxis. Other trials have focused on the development of novel calcineurin inhibitors (voclosporin), costimulation blockade (ASKP1240 and alefacept), kinase inhibitors (tofacitinib and sotrastaurin), and inhibitors of leukocyte migration (efalizumab). While these later agents have not been FDA-approved for use in transplantation, they remain noteworthy, as these agents explore pathways not previously targeted for allograft-rejection prophylaxis.
    [Show full text]
  • Voclosporin (Lupkynis™) EOCCO POLICY
    voclosporin (Lupkynis™) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO232 Description Voclosporin (Lupkynis) is an orally administered calcineurin-inhibitor . Length of Authorization Initial: Six months Renewal: 12 months Quantity Limits Product Name Dosage Form Indication Quantity Limit voclosporin 7.9 mg capsules Lupus Nephritis 180 capsules/30 days (Lupkynis) Initial Evaluation I. Voclosporin (Lupkynis) may be considered medically necessary when the following criteria below are met: A. Member is 18 years of age or older; AND B. Medication is prescribed by, or in consultation with, a rheumatologist or nephrologist; AND C. Not used in combination with biologic(s) [e.g., rituximab (Rituxan), abatacept (Orencia), belimumab (Benlysta)]; AND D. A confirmed positive autoantibody test [antinuclear (ANA) and/or anti-double-stranded DNA (anti-ds-DNA)]; AND E. A diagnosis of Lupus Nephritis (LN); AND 1. Biopsy indicating class III (focal), IV (diffuse), or V (membranous) LN; AND 2. Biopsy shows active lesions; OR i. Biopsy shows active AND chronic lesions; AND 3. Provider attestation indicating medication will be given in combination with mycophenolate (CellCept) for induction and maintenance; AND 4. Provider attestation the member will continue to receive standard therapy (e.g., antimalarials, NSAIDs, immunosuppressives, corticosteroids), unless all are contraindicated or not tolerated; AND 5. Treatment with belimumab (Benlysta) has been ineffective, contraindicated, or not tolerated. 1 voclosporin (Lupkynis™) EOCCO POLICY II. Voclosporin (Lupkynis) is considered investigational when used for all other conditions, including but not limited to: A. Systemic Lupus Erythematosus (SLE) with absence of lupus nephritis B. Severe active central nervous system lupus C. Renal transplantation Renewal Evaluation I.
    [Show full text]
  • Lupus Prior Authorization with Quantity Limit Program Summary
    Lupus Prior Authorization with Quantity Limit Program Summary Benlysta® (belimumab) Prior Authorization with Quantity Limit TARGET AGENT(S) Benlysta® (belimumab) Lupkynis™ (voclosporin) Brand (generic) GPI Multisource Quantity Limit Code (per day or as listed) Benlysta (belimumab) 120 mg vial 99422015002120 M, N, O, or Y N/A 400 mg vial 99422015002140 M, N, O, or Y N/A 200 mg/mL autoinjector 9942201500D520 M, N, O, or Y 4 prefilled autoinjectors/ 28 days 200 mg/mL prefilled 9942201500E520 M, N, O, or Y 4 prefilled syringes/ 28 days syringe Lupkynis (voclosporin) 7.9 mg capsule 99402080000120 M, N, O, or Y 6 capsules PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Initial Evaluation Target Agent(s) will be approved when ALL of the following are met: 1. ONE of the following: 1. The requested agent is eligible for continuation of therapy AND ONE of the following: i. Information has been provided that indicates the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days OR ii. The prescriber states that the patient has been treated with the requested agent within the past 90 days AND is at risk if therapy is changed Agents Eligible for Continuation of Therapy All target agents are eligible OR 2. The patient has a diagnosis of active systemic lupus erythematosus (SLE) disease WITHOUT active Lupus Nephritis AND ALL of the following: i. The requested agent is FDA approved for SLE AND ii. BOTH of the following: a. ONE of the following: a. The patient has tried and had an inadequate response to hydroxychloroquine OR Boeing_PS_Lupus_PAQL_ProgSum_AR0521 Page 1 of 5 © Copyright Prime Therapeutics LLC.
    [Show full text]